Methoxy polyethylene glycol-epoetin beta: new drug. Pegylated epoetin beta: risk of cardiovascular disorders.
No tangible benefit, but a risk of cardiovascular adverse effects due to haemogloblin levels that are frequently too high compared with other epoetins.
D000740:Anemia / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004338:Drug Combinations; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005060:Europe; D006801:Humans; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D004338:Drug Combinations; D004921:Erythropoietin; D011092:Polyethylene Glycols